Literature DB >> 33189539

Correlation and Agreement of Yttrium-90 Positron Emission Tomography/Computed Tomography with Ex Vivo Radioembolization Microsphere Deposition in the Rabbit VX2 Liver Tumor Model.

Andrew C Gordon1, Vanessa L Gates2, Sarah B White3, Kathleen R Harris2, Daniel Procissi2, Zhuoli Zhang2, Weiguo Li2, Donald Samaan4, Jodi R Nicolai2, Samdeep K Mouli2, Kent T Sato2, Robert K Ryu5, Reed A Omary6, Riad Salem7, Robert J Lewandowski7, Andrew C Larson8.   

Abstract

PURPOSE: To demonstrate a stronger correlation and agreement of yttrium-90 (90Y) positron emission tomography (PET)/computed tomography (CT) measurements with explant liver tumor dosing compared with the standard model (SM) for radioembolization.
MATERIALS AND METHODS: Hepatic VX2 tumors were implanted into New Zealand white rabbits, with growth confirmed by 7 T magnetic resonance imaging. Seventeen VX2 rabbits provided 33 analyzed tumors. Treatment volumes were calculated from manually drawn volumes of interest (VOI) with three-dimensional surface renderings. Radioembolization was performed with glass 90Y microspheres. PET/CT imaging was completed with scatter and attenuation correction. Three-dimensional ellipsoid VOI were drawn to encompass tumors on fused images. Tumors and livers were then explanted for inductively coupled plasma (ICP)-optical emission spectroscopy (OES) analysis of microsphere content. 90Y PET/CT and SM measurements were compared with reference standard ICP-OES measurements of tumor dosing with Pearson correlation and Bland-Altman analyses for agreement testing with and without adjustment for tumor necrosis.
RESULTS: The median infused activity was 33.3 MBq (range, 5.9-152.9). Tumor dose was significantly correlated with 90Y PET/CT measurements (r = 0.903, P < .001) and SM estimates (r = 0.607, P < .001). Bland-Altman analyses showed that the SM tended to underestimate the tumor dosing by a mean of -8.5 Gy (CI, -26.3-9.3), and the degree of underestimation increased to a mean of -18.3 Gy (CI, -38.5-1.9) after the adjustment for tumor necrosis.
CONCLUSIONS: 90Y PET/CT estimates were strongly correlated and had better agreement with reference measurements of tumor dosing than SM estimates.
Copyright © 2020 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33189539      PMCID: PMC8086791          DOI: 10.1016/j.jvir.2020.09.016

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  33 in total

Review 1.  Measuring agreement in method comparison studies.

Authors:  J M Bland; D G Altman
Journal:  Stat Methods Med Res       Date:  1999-06       Impact factor: 3.021

2.  Analysis of the distribution of intra-arterial microspheres in human liver following hepatic yttrium-90 microsphere therapy.

Authors:  A M Campbell; I H Bailey; M A Burton
Journal:  Phys Med Biol       Date:  2000-04       Impact factor: 3.609

3.  MIRD pamphlet No. 17: the dosimetry of nonuniform activity distributions--radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee.

Authors:  W E Bolch; L G Bouchet; J S Robertson; B W Wessels; J A Siegel; R W Howell; A K Erdi; B Aydogan; S Costes; E E Watson; A B Brill; N D Charkes; D R Fisher; M T Hays; S R Thomas
Journal:  J Nucl Med       Date:  1999-01       Impact factor: 10.057

4.  Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma.

Authors:  Andrew C Gordon; Ahmed Gabr; Ahsun Riaz; Omar M Uddin; Nadine Abouchaleh; Rehan Ali; Joseph Kallini; Riad Salem; Robert J Lewandowski
Journal:  Cardiovasc Intervent Radiol       Date:  2018-06-12       Impact factor: 2.740

5.  Radioembolization for hepatocellular carcinoma: Statistical confirmation of improved survival in responders by landmark analyses.

Authors:  Ahsun Riaz; Ahmed Gabr; Nadine Abouchaleh; Rehan Ali; Ali Al Asadi; Ronald Mora; Laura Kulik; Kush Desai; Bartley Thornburg; Samdeep Mouli; Ryan Hickey; Frank H Miller; Vahid Yaghmai; Daniel Ganger; Robert J Lewandowski; Riad Salem
Journal:  Hepatology       Date:  2018-01-26       Impact factor: 17.425

6.  Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.

Authors:  Etienne Garin; Yan Rolland; Julien Edeline; Nicolas Icard; Laurence Lenoir; Sophie Laffont; Habiba Mesbah; Mathias Breton; Laurent Sulpice; Karim Boudjema; Tanguy Rohou; Jean-Luc Raoul; Bruno Clement; Eveline Boucher
Journal:  J Nucl Med       Date:  2015-02-12       Impact factor: 10.057

7.  Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection.

Authors:  Michael Vouche; Robert J Lewandowski; Rohi Atassi; Khairuddin Memon; Vanessa L Gates; Robert K Ryu; Ron C Gaba; Mary F Mulcahy; Talia Baker; Kent Sato; Ryan Hickey; Daniel Ganger; Ahsun Riaz; Jonathan Fryer; Juan Carlos Caicedo; Michael Abecassis; Laura Kulik; Riad Salem
Journal:  J Hepatol       Date:  2013-06-25       Impact factor: 25.083

8.  The number of microspheres in Y90 radioembolization directly affects normal tissue radiation exposure.

Authors:  Alexander S Pasciak; Godwin Abiola; Robert P Liddell; Nathan Crookston; Sepideh Besharati; Danielle Donahue; Richard E Thompson; Eric Frey; Robert A Anders; Matthew R Dreher; Clifford R Weiss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-18       Impact factor: 9.236

9.  A Comparison of Techniques for (90)Y PET/CT Image-Based Dosimetry Following Radioembolization with Resin Microspheres.

Authors:  Alexander S Pasciak; Austin C Bourgeois; Yong C Bradley
Journal:  Front Oncol       Date:  2014-05-22       Impact factor: 6.244

10.  Percutaneous ultrasound guided implantation of VX2 for creation of a rabbit hepatic tumor model.

Authors:  Sarah B White; Jeane Chen; Andrew C Gordon; Kathleen R Harris; Jodi R Nicolai; Derek L West; Andrew C Larson
Journal:  PLoS One       Date:  2015-04-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.